New Grant Funds Study to Develop Better Diabetes Drugs

By Eric Sauter

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure.

Douglas Kojetin, a TSRI associate professor, is the principal investigator for the new five-year study.

The study will take a cue from the two mainstays of type 2 diabetes treatment—pioglitazone (Actos) and rosiglitazone (Avandia). Both drugs raise the body’s sensitivity to insulin, increasing the amount of glucose or sugar absorbed by the cells.

Studies have shown, however, that while these and other recently developed drugs are designed to bind to a specific site on the PPAR gamma (PPARG) nuclear receptor, they can also bind to an alternative site.

“This unexpected finding opens a lot of potential opportunities,” Kojetin said. “We’re looking to design a molecule that blocks both sites and can be used to probe what this alternative binding does on a molecular level—with the hope that this information will help us come up with a better drug model.”

The number of the new National Institutes of Health grant is 1R01DK101871.

Send comments to: press[at]scripps.edu

kojetin
TSRI Associate Professor Douglas Kojetin is the principal investigator for the new five-year study. (Photo by James McEntee.)

SEARCH NEWS & VIEWS

To Mark Territory or Not to Mark Territory: Breaking the Pheromone Code

Scientists Reveal Molecular Secrets Behind Resveratrol’s Health Benefits

New Grant Funds Study to Develop Better Diabetes Drugs

New Grant Funds Study to Develop Better Diabetes Drugs